Abbvie Inc
NYSE:ABBV
Abbvie Inc
Pre-Tax Income
Abbvie Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$6.9B
|
CAGR 3-Years
60%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$7.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
Moderna Inc
NASDAQ:MRNA
|
Pre-Tax Income
-$3.9B
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
19%
|
See Also
What is Abbvie Inc's Pre-Tax Income?
Pre-Tax Income
6.3B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Pre-Tax Income amounts to 6.3B USD.
What is Abbvie Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
2%
Over the last year, the Pre-Tax Income growth was -54%. The average annual Pre-Tax Income growth rates for Abbvie Inc have been 23% over the past three years , 4% over the past five years , and 2% over the past ten years .